Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma

Akihiro Katayama1, Takeshi Ogino, Nobuyuki Bandoh

  • 1Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, Asahikawa, Japan.

Abstract

Insights

CXCR4 (C-X-C chemokine receptor type 4) is highly expressed in head and neck squamous cell carcinomas (HNSCC), driving tumor cell migration and proliferation. Down-regulating CXCR4 may offer a therapeutic strategy for HNSCC metastasis.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • CXCR4 (C-X-C chemokine receptor type 4) and its ligand SDF-1 (stromal cell-derived factor-1) are implicated in various carcinomas.
  • The role of CXCR4 in head and neck squamous cell carcinomas (HNSCC) is not well understood.

Purpose of the Study:

  • To investigate CXCR4 expression and function in HNSCC cell lines.
  • To explore the regulation of CXCR4 by cytokines (IL-1β, TNF-α, IFN-γ).
  • To correlate CXCR4 expression with clinical features in HNSCC patients.

Main Methods:

  • Analysis of CXCR4 expression in six HNSCC cell lines using RT-PCR and flow cytometry.
  • Assays for SDF-1-mediated cell migration and proliferation.
  • Western blot analysis of signaling pathways (ERK1/2, Akt).
  • Immunohistologic analysis of 56 HNSCC patient biopsy specimens.

Main Results:

  • Significant CXCR4 expression was detected in specific HNSCC cell lines.
  • SDF-1 stimulation enhanced migration and proliferation in CXCR4-positive cells, activating ERK1/2 and Akt pathways.
  • IFN-γ significantly reduced CXCR4 expression and SDF-1-induced cellular activities.
  • High CXCR4 expression correlated with advanced neck status, distant metastasis, and shorter cause-specific survival in HNSCC patients.
  • Multivariate analysis identified CXCR4 positivity as an independent predictor of cause-specific death.

Conclusions:

  • CXCR4 plays a significant role in HNSCC progression and metastasis.
  • Targeting CXCR4 may represent a potential therapeutic strategy for HNSCC.